Allergan’s intravitreal implant wins approval in China

Allergan (NYSE:AGN) said today that it landed an imported drugs license from the Chinese FDA to market its dexamethasone intravitreal implant, Ozurdex, as a treatment for adults with macular edema following branch retinal vein occlusion or central retinal vein occlusion.

The Dublin-based pharma giant touted its therapy as the first intravitreal injection approved for RVO in China.

Get the full story at our sister site, Drug Delivery Business News.

The post Allergan’s intravitreal implant wins approval in China appeared first on MassDevice.

from MassDevice http://ift.tt/2gVf7gz